Skip to content
ESPT
MARKETS / NYSE / Health care / Pharmaceuticals / JNJ
NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Johnson & Johnson JNJ

19 fiscal years on record · USD · FY2025 reported · SEC filings only
18 YEARS OF DIVIDEND GROWTH
$94.2B
▲ 6.0% YoY
$26.8B
▲ 90.6% YoY
$19.7B
▼ 0.7% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Johnson & Johnson, with its subsidiaries, is engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The company and its subsidiaries have approximately 138,200 employees worldwide. Its operating companies conduct business in virtually all countries of the world. The company is organized into two business segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on the therapeutic areas of oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism, with medicines distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The MedTech segment develops and manufactures a broad portfolio of products used in cardiovascular, orthopaedics, surgery, and vision, supporting physicians, hospitals, eye care professionals and healthcare systems. It was incorporated in the State of New Jersey in 1887.

Written from the business description in JOHNSON & JOHNSON's annual report to the U.S. Securities and Exchange Commission, filed 11 February 2026. Every sentence was checked against that document before publication.

Growth

USD 94.2B
Revenue, FY2025 · full 19-year series below
Revenue $B Net income $B
FY2025 · Revenue 94.2 · Net income 26.8
40B80B
2007201020132016201920222025
Compound annual growth
+5.6%
+2.7%
+3.0%
+2.9%
+14.3%
+12.7%
+5.7%
+4.8%
+17.9%
+14.9%
+7.2%
+5.7%
+4.9%
+5.2%
+5.7%
+6.1%
−0.5%
+13.1%
+1.2%
+9.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +2.7% a year over the five years to FY2025 — but profit grew faster: net income at +12.7%, earnings per share at +14.9%.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

28 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 34.6% · Net 28.5%
20%40%
200720162025
ROE
FY2025 · ROE 35.0%
20%40%
200720162025
Three returns, three denominators.
Return on capital employedNot available: we don't have a clean operating profit figure for this period.
Gross margin67.9%
Operating margin34.6%
Net margin28.5%
EBITDAUSD 40.1B

Each USD of equity produced 35 cents of profit this year.

Cash & shareholders

USD 6.0B
returned in FY2025 · dividends + net buybacks
Free cash flow $B
FY2025 · FCF 19.7
10B20B
200720162025
Net buybacks $B Dividends $B
FY2025 · Dividends · · Net buybacks 6.0
5B10B
2007201020132016201920222025
Dividends paid·
Net buybacksUSD 6.0B
Share of profit22.2%
Consecutive raises18 years

USD 6.0B in buybacks — 22% of the year's profit went back to shareholders.

Total assetsUSD 199.2B
CashUSD 19.7B
Gross debtUSD 41.4B
Net debtUSD 21.7B
Current ratio1.03×

Net debt stands at 27% of equity.

The 19-year record

19 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
JNJ, 19-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B94.288.885.280.078.782.682.181.676.571.970.174.371.367.265.061.661.963.761.1
Operating income $B32.616.715.119.419.216.517.3◌◌◌◌21.616.415.013.817.716.6◌◌
EBITDA $B40.124.022.526.326.623.724.3◌◌◌◌25.520.518.616.920.619.4◌◌
Income tax $B5.82.61.73.01.41.82.22.716.43.33.84.21.63.32.73.63.54.02.7
Net income $B26.814.135.217.920.914.715.115.31.316.515.416.313.810.99.713.312.312.910.6
Free cash flow $B19.719.818.217.219.820.219.918.517.815.516.115.013.812.511.414.014.211.912.1
EPS, diluted $11.035.7913.726.737.815.515.635.610.475.935.485.704.813.863.494.784.404.573.63
Dividend / sh $5.144.914.704.454.193.983.753.543.323.152.952.762.592.402.252.111.931.791.62
Payout % — not applicable: no dividend———————————————————
ROE %35.020.148.323.830.424.025.425.52.023.421.922.719.917.817.024.926.430.224.4

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

Johnson & JohnsonvsELI Lilly & Co.Same industry: Pharmaceutical PreparationsJohnson & JohnsonvsMerck & Co. Inc.Same industry: Pharmaceutical PreparationsJohnson & JohnsonvsPfizer Inc.Same industry: Pharmaceutical PreparationsJohnson & JohnsonvsAbbVie Inc.Same industry: Pharmaceutical PreparationsJohnson & JohnsonvsAstraZeneca PLCSame industry: Pharmaceutical PreparationsJohnson & JohnsonvsNovartis AGSame industry: Pharmaceutical PreparationsJohnson & JohnsonvsBristol Myers Squibb Co.Same industry: Pharmaceutical Preparations
More in this sector

Other companies filing in the same sector

MCK · COR · CAH · HCA · LLY · MRK
Provenance

Company facts, as filed

How we verify · 0 failures in 93 reconciliationsAUDITED

Reconciled in 19 of the 19 fiscal years we could check. Two checks were skipped: the balance sheet is not tagged before 2008.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNYSE
Incorporated inNew Jersey
Fiscal year endsJanuary 3
Data on record since2007

Share this section

Download image